Komal Jhaveri, MD, FACP

Komal Jhaveri, MD, FACP, is the section head of the Endocrine Therapy Research Program, clinical director of the Early Drug Development Service, and Patricia and James Cayne Chair for Junior Faculty at Memorial Sloan Kettering Cancer Center

Articles

Dr Jhaveri on the FDA Approval of Imlunestrant for ESR1+ Breast Cancer

December 5th 2025

Komal Jhaveri, MD, FACP, discusses the clinical implications of the FDA approval of imlunestrant for pretreated, ESR1-mutated advanced breast cancer.

Dr Jhaveri on the Association Between ADCs and Ocular Toxicities in Breast Cancer

October 31st 2025

Komal Jhaveri, MD, FACP, discusses ocular toxicities that can be seen with the use of ADCs when treating patients with breast cancer.

Identifying Unmet Needs and Remaining Questions

October 3rd 2025

Panelists discuss how the rapidly evolving breast cancer treatment landscape includes promising developments in oral selective estrogen receptor degraders (SERDs), CDK4/6 inhibitor sequencing strategies, and antibody-drug conjugates (ADCs), with new targeted therapies and bispecifics continuing to emerge.

Treatment Options in the 2L for HER2-Low Disease Including ADCs and Endocrine Therapy

October 2nd 2025

Panelists discuss how treatment decisions between antibody-drug conjugates (ADCs) and continued endocrine-based therapies in HER2-low disease depend on endocrine sensitivity, with ADCs reserved for endocrine-refractory tumors or primary endocrine-resistant cases with short initial response durations.

Evaluating the ASCENT-04 Trial Results in Triple-Negative Disease

October 2nd 2025

Panelists discuss how the ASCENT-04 trial findings establish sacituzumab govitecan (SG)plus pembrolizumab as an active standard-of-care combination for triple-negative breast cancer, with considerations needed for patients with prior immunotherapy exposure.

The Role of T-DXd in the Frontline Setting for HER2+ mBC and Treatment Personalization

October 1st 2025

Panelists discuss how DESTINY-Breast09 data support trastuzumab deruxtecan (T-DXd) plus pertuzumab in frontline HER2-positive disease for select patients with extensive disease or brain metastases while emphasizing individualized treatment decisions to avoid overtreatment.

CDK4/6 Inhibitor Sequencing in the Metastatic Setting and Maintenance Strategies Following THP Induction

October 1st 2025

Panelists discuss how prior adjuvant CDK4/6 inhibitor exposure complicates metastatic treatment decisions, with limited data supporting rechallenge strategies and the need for more targeted therapies such as CDK2- or CDK4-specific inhibitors.

CDK4/6 Inhibitor Combination Therapy in HER2+ Disease

September 24th 2025

Panelists discuss how the PATINA trial findings demonstrate significant progression-free survival benefit from adding palbociclib to endocrine and HER2-targeted therapy in patients with estrogen receptor (ER)–positive, HER2-positive disease following induction chemotherapy, though access challenges remain in clinical practice.

Considering the Oral SERD and PROTAC Toxicity Profiles

September 24th 2025

Panelists discuss how the well-tolerated safety profiles of oral selective estrogen receptor degraders (SERDs) and proteolysis-targeting chimeras (PROTACs), despite some low-grade toxicities such as bradycardia and photopsia, make them attractive options, with treatment decisions potentially influenced by specific adverse effect considerations and monitoring requirements.

Combination Treatment Options for Patients With ESR1 Mutation and Comutations

September 17th 2025

Panelists discuss how treatment approaches for patients with both ESR1 mutations and PI3K pathway alterations currently rely on single-agent elacestrant for slow-growing disease or doublet therapies for more aggressive cases, with the field rapidly evolving toward targeted combination therapies.

Emerging Oral SERD and PROTAC Treatment Options as Monotherapy and in Combination

September 17th 2025

Panelists discuss how proteolysis-targeting chimera (PROTAC) agents such as vepdegestrant offer a different mechanism of action compared with oral selective estrogen receptor degrader (SERDs), with promising clinical activity in ESR1-mutant tumors and the need for more data on optimal sequencing strategies.

Evaluating Longitudinal ctDNA Testing for Molecular Progression During CDK4/6 Inhibitor Therapy

September 8th 2025

Panelists discuss how longitudinal surveillance testing could enable treatment interventions based on molecular progression (ESR1 mutations) rather than waiting for radiographic progression, though questions remain about overall survival impact.

The Impact of Oral SERDs on the Changing Treatment Landscape

September 8th 2025

Panelists discuss how oral selective estrogen receptor degraders (SERDs) such as elacestrant are changing treatment for patients experiencing progression on CDK4/6 inhibitors, with current approval for ESR1-mutant tumors and anticipation of additional approvals for other oral SERDs in development.

Dr Jhaveri on the Evolving Role of Inavolisib in PIK3CA-Mutated Metastatic Breast Cancer

April 18th 2025

Komal Jhaveri, MD, FACP, discusses the success of the INAVO120 trial of inavolisib/palbociclib/fulvestrant in PIK3CA-mutated metastatic breast cancer.

Inavolisib Has a Favorable Risk-Benefit Profile for PIK3CA-Mutant, HR+ Metastatic Breast Cancer: With Komal Jhaveri, MD, FACP

February 17th 2025

Dr Jhaveri discusses advice for managing inavolisib-related adverse effects and best practices for biomarker testing in patients with HR+ breast cancer.

Dr Jhaveri on the Use of CDK4/6 Inhibitors Plus Endocrine Therapy in Breast Cancer

September 9th 2024

Jhaveri on the INAVO120 Trial of Inavolisib/Palbociclib/Fulvestrant in PIK3CA -Mutant, HR+ Breast Cancer

August 22nd 2024

Dr Jhaveri discusses the INAVO120 trial of inavolisib plus palbociclib and fulvestrant in PIK3CA-mutant, HR-positive metastatic breast cancer.

Dr Jhaveri on the Evolution of Treatment With ADCs in HER2-Expressing Breast Cancer

July 17th 2024

Komal Jhaveri, MD, FACP, discusses the evolution of antibody-drug conjugates for patients with HER2-positive, HER2-low or HER2-ultralow metastatic breast cancer.

Dr Jhaveri on the Implications of DESTINY-Breast06 for HR+/HER2-Low and -Ultralow Breast Cancer

July 1st 2024

Komal Jhaveri, MD, FACP, discusses the implications of the DESTINY-Breast06 trial for hormone receptor–positive, HER2-low and -ultralow breast cancer.

Dr Jhaveri on the Implications of Treatment With RLY-2608 in Advanced ER+ Breast Cancer

June 7th 2024

Komal Jhaveri, MD, FACP, discusses the implications of investigating treatment with RLY-2608 in patients with PIK3CA-mutant advanced ER+ breast cancer.